4BIO Capital led Cloverleaf Bio's $33M seed round.
Published
Signal category
Capital & Finance
Quote
“Pumped to have led Cloverleaf Bio's $33M seed round.”
— Dima Kuzmin|4BIO Capital team
Company
4BIO Capital
London-based venture fund investing in advanced therapies
- Industry
- Venture Capital and Private Equity Principals
- Location
- London, GB
- Company size
- 20 employees
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, please visit www.4biocapital.com
Founded 2014